143 related articles for article (PubMed ID: 35209006)
41. Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies.
Rajagopal K; Varakumar P; Aparna B; Byran G; Jupudi S
J Biomol Struct Dyn; 2021 Sep; 39(15):5551-5562. PubMed ID: 32720578
[TBL] [Abstract][Full Text] [Related]
42. Metal-Bound Methisazone; Novel Drugs Targeting Prophylaxis and Treatment of SARS-CoV-2, a Molecular Docking Study.
Abdelaal Ahmed Mahmoud M Alkhatip A; Georgakis M; Montero Valenzuela LR; Hamza M; Farag E; Hodgkinson J; Hosny H; Kamal AM; Wagih M; Naguib A; Yassin H; Algameel H; Elayashy M; Abdelhaq M; Younis MI; Mohamed H; Abdulshafi M; Elramely MA
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804129
[TBL] [Abstract][Full Text] [Related]
43. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro.
Swain SS; Singh SR; Sahoo A; Panda PK; Hussain T; Pati S
Proteins; 2022 Sep; 90(9):1617-1633. PubMed ID: 35384056
[TBL] [Abstract][Full Text] [Related]
44. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
[TBL] [Abstract][Full Text] [Related]
45. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.
Anirudhan V; Lee H; Cheng H; Cooper L; Rong L
J Med Virol; 2021 May; 93(5):2722-2734. PubMed ID: 33475167
[TBL] [Abstract][Full Text] [Related]
46. Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach.
Fadaka AO; Aruleba RT; Sibuyi NRS; Klein A; Madiehe AM; Meyer M
J Biomol Struct Dyn; 2022 May; 40(8):3416-3427. PubMed ID: 33200673
[TBL] [Abstract][Full Text] [Related]
47. Discovery of a "Cocktail" of Potential SARS-COV-2 Main Protease Inhibitors through Virtual Screening of Known Chemical Components of Vitex negundo L. ("Lagundi").
Cayona R; Creencia E
Med Chem; 2022; 18(3):364-381. PubMed ID: 34148541
[TBL] [Abstract][Full Text] [Related]
48.
Eissa IH; Khalifa MM; Elkaeed EB; Hafez EE; Alsfouk AA; Metwaly AM
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684735
[TBL] [Abstract][Full Text] [Related]
49. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
50. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2.
Weglarz-Tomczak E; Tomczak JM; Talma M; Burda-Grabowska M; Giurg M; Brul S
Sci Rep; 2021 Feb; 11(1):3640. PubMed ID: 33574416
[TBL] [Abstract][Full Text] [Related]
51. Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease.
Hognon C; Marazzi M; García-Iriepa C
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628665
[TBL] [Abstract][Full Text] [Related]
52. Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model.
Tan B; Zhang X; Ansari A; Jadhav P; Tan H; Li K; Chopra A; Ford A; Chi X; Ruiz FX; Arnold E; Deng X; Wang J
Science; 2024 Mar; 383(6690):1434-1440. PubMed ID: 38547259
[TBL] [Abstract][Full Text] [Related]
53. Potential SARS-CoV-2 protease M
Kouznetsova VL; Huang DZ; Tsigelny IF
Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
[TBL] [Abstract][Full Text] [Related]
54. Ligand-based design, synthesis, computational insights, and
Elagawany M; Elmaaty AA; Mostafa A; Abo Shama NM; Santali EY; Elgendy B; Al-Karmalawy AA
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2112-2132. PubMed ID: 35912578
[TBL] [Abstract][Full Text] [Related]
55. Discovery of Potential SARS-CoV-2 Papain-like Protease Natural Inhibitors Employing a Multi-Phase In Silico Approach.
Elkaeed EB; Metwaly AM; Alesawy MS; Saleh AM; Alsfouk AA; Eissa IH
Life (Basel); 2022 Sep; 12(9):. PubMed ID: 36143445
[TBL] [Abstract][Full Text] [Related]
56. On the search for COVID-19 therapeutics: identification of potential SARS-CoV-2 main protease inhibitors by virtual screening, pharmacophore modeling and molecular dynamics.
Hassan A; Arafa RK
J Biomol Struct Dyn; 2022 Oct; 40(17):7815-7828. PubMed ID: 33749545
[TBL] [Abstract][Full Text] [Related]
57. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
58. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
Molecules; 2020 May; 25(11):. PubMed ID: 32485894
[TBL] [Abstract][Full Text] [Related]
59. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
60. Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment.
Swain SS; Singh SR; Sahoo A; Hussain T; Pati S
J Biomol Struct Dyn; 2022 Sep; 40(14):6463-6476. PubMed ID: 33583350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
